

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Yamamoto et al. Art Unit : 1628  
Patent No. : 7,994,159 Examiner : Anna Pagonakis  
Issue Date : August 9, 2011 Conf. No. : 3373  
Serial No. : 10/797,903  
Filed : March 10, 2004  
Title : C-KIT KINASE INHIBITORS

Attn.: Certificate of Corrections Branch  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL OF REQUEST FOR CERTIFICATE OF CORRECTION

Applicant hereby requests that a certificate of correction be issued for the above patent in accordance with the attached request.

Regarding the cancellation of issued claim 3 (original claim 16), Applicants believe that the claim was included inadvertently and should have been cancelled in the Examiner's Amendment in the Notice of Allowance dated March 10, 2011 (herein attached). The Examiner's intention to cancel the claim is evident by the explicit recitation of the allowed claim numbers (i.e., claims 12, 14, 17, 18 and 20-37) and in the deletion of all reference to claim 16 as shown on page 3 of the Notice of Allowance. In addition, the Examiner withdrew claim 16 as being drawn to a nonelected invention in the Office Actions dated August 20, 2009; April 1, 2010; and September 1, 2010 (herein attached). The Examiner further indicated to Applicants Attorney the necessity of cancelling claim 16 in the telephonic interview of December 20, 2010.

One or more of the errors sought to be corrected were made by applicant. Please charge Deposit Account No. 06-1050 to cover the required fee of 37 CFR § 1.20(a).

CERTIFICATE OF (A) MAILING BY FIRST CLASS MAIL OR (B) TRANSMISSION  
I hereby certify under 37 CFR §1.8(a) that this correspondence is either (A) addressed as set out in 37 CFR §1.1(a) and being deposited with the United States Postal Service as first class mail with sufficient postage, or (B) being transmitted by facsimile in accordance with 37 CFR § 1.6(d) or via the Office electronic filing system in accordance with 37 CFR § 1.6(a)(4), on the date indicated below.

January 13, 2012

Date of Deposit or Transmission

/Meredith Mescher/

Signature

Meredith Mescher

Typed or Printed Name of Person Signing Certificate

Applicant : Yamamoto et al.  
Patent No. : 7,994,159  
Issued : August 9, 2011  
Serial No. : 10/797,903  
Filed : March 10, 2004  
Page : 2 of 2

Attorney's Docket No.: 25142-0002001 / FP04-0096-  
00US-XX

Please apply any other charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: January 13, 2012

/Angela D. Follett/

Angela D. Follett, Ph.D.  
Reg. No. 60,365

Customer Number 26211  
Fish & Richardson P.C.  
Telephone: (612) 335-5070  
Facsimile: (877) 769-7945

60722931.doc

Staple  
Here  
OnlyUNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTIONPage 1 of 3

PATENT NO. :: 7,994,159

APPLICATION NO. :: 10/797,903

DATED :: AUGUST 9, 2011

INVENTOR(S) :: YUJI YAMAMOTO

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 18, line 1 (Claim 1), please delete “cKit” and insert -- c-Kit --, therefor;

Column 18, line 6 (Claims 1), please delete “quinolinecarboxamide,” and insert -- quinolinecarboxamide; --, therefor;

Column 18, lines 14-15 (Claim 2), please delete “gastointestinal” and insert -- gastrointestinal --, therefor;

Column 18, lines 16-54 (Claim 3), please **delete** claim 3.

Column 18, line 62 (Claim 4), please delete “cKit” and insert -- c-Kit --, therefor;

Column 18-19, lines 55-67 and lines 1-5 please **delete** “4. A method of inhibiting c-kit activity in a cancer cell in a patient comprising:

a) determining if a cell expresses c-Kit kinase or a mutant c-Kit kinase; and  
b) if the cell is determined to express c-Kit kinase or a mutant c-Kit kinase, applying to the cell

a pharmacologically effective dose to inhibit c-Kit activity of said cKit kinase or mutant c-Kit kinase of a compound selected from the group consisting of:

4-(3-chloro-4- (cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide;

## MAILING ADDRESS OF SENDER:

Angela D. Follett  
Fish & Richardson P.C.  
P.O. Box 1022  
Minneapolis, Minnesota 55440-1022

Staple  
Here  
Only**UNITED STATES PATENT AND TRADEMARK OFFICE**  
**CERTIFICATE OF CORRECTION**

Page 2 of 3

PATENT NO. :: 7,994,159

APPLICATION NO. :: 10/797,903

DATED :: AUGUST 9, 2011

INVENTOR(S) :: YUJI YAMAMOTO

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; and

N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, or a pharmaceutically acceptable salt thereof."

and **insert - - 4.** A method of inhibiting c-kit activity in a cancer cell in a patient comprising:

a) determining if a cell expresses c-Kit kinase or a mutant c-Kit kinase; and  
b) if the cell is determined to express c-Kit kinase or a mutant c-Kit kinase, applying to the cell

a pharmacologically effective dose to inhibit c-Kit activity of said c-Kit kinase or mutant c-Kit kinase of a compound selected from the group consisting of:

4-(3-chloro-4- (cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide;

4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; and

N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, or a pharmaceutically acceptable salt thereof. - -, therefor.

## MAILING ADDRESS OF SENDER:

Angela D. Follett  
Fish & Richardson P.C.  
P.O. Box 1022  
Minneapolis, Minnesota 55440-1022

Staple  
Here  
Only

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 3 of 3

PATENT No. :: 7,994,159

APPLICATION NO :: 10/797,903

DATED :: AUGUST 9, 2011

INVENTOR(S) :: YUJI YAMAMOTO

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 19, line 10 (Claim 6), please delete “compound)” and insert - - compound - -, therefor.

### MAILING ADDRESS OF SENDER:

Angela D. Follett  
Fish & Richardson P.C.  
P.O. Box 1022  
Minneapolis, Minnesota 55440-1022